Under the five-year collaboration agreement, Bayer and Schrödinger aim to develop a virtual platform, which will be able to enumerate, screen and design synthetically feasible compounds – potentially leading to the development and optimization of new therapeutic candidates.
The collaborative work will be based on Schrödinger’s molecular design technology and machine learning capabilities, while Bayer, on its side, will provide the in silico models that are able to predict the absorption, distribution, metabolism, excretion, toxicity and chemical synthesizability of the compounds.
A spokesperson for the company could not specify the therapeutic target areas that will be worked on through this partnership.
The software will be built leveraging Schrödinger’s LiveDesign platform, a digital platform enabling the in silico design of therapeutic candidates.
On its website, Schrödinger states that its platform is capable of evaluating billions of molecules per week with a high degree of accuracy.
The most ‘promising’ compounds that emerge from each round of experimental project chemistry conducted on Schrödinger’s platform are subsequently optimized through additional cycles of computation analysis.
Earlier this year, Schrödinger announced an extension of its collaborative work with Morphic Therapeutic on the development of treatments for fibrosis, Crohn’s disease, and inflammatory bowel disease.